The Lymphoma Channel on VJHemOnc is an independent medical education platform, supported with funding from AstraZeneca (Diamond), BMS (Gold), Johnson & Johnson (Gold), Takeda (Silver) and Galapagos (Bronze). Supporters have no influence on the production of content. The levels of sponsorship listed are reflective of the amount of funding given.
ASH 2023 | Golcadomide, a novel CELMoD agent, with R-CHOP in patients with untreated a-BCL
Marc Hoffmann, MD, The University of Kansas, Kansas City, KS, discusses the results from the dose escalation and expansion phases of the ongoing CC-220-DLBCL-001 trial (NCT04884035), which aims to assess the safety and efficacy of golcadomide, a novel CELMoD agent, in combination with R-CHOP (rituximab, cyclophosphamide, doxorubicin, vincristine, and prednisone) for the treatment of previously untreated aggressive B-cell lymphoma (a-BCL). This therapy approach has shown promising response rates and will now be investigated in a large randomized Phase III trial. This interview took place at the 65th ASH Annual Meeting and Exposition, held in San Diego, CA.
These works are owned by Magdalen Medical Publishing (MMP) and are protected by copyright laws and treaties around the world. All rights are reserved.
Disclosures
Consultancy: Pharmacyclics LLC (an AbbVie Company)
Honoraria: Pharmacyclics LLC (an AbbVie Company)
